Overview
DCC plc is a multinational corporation based in Dublin, Ireland, primarily engaged in the energy, healthcare, and technology sectors. The company operates a diversified business model focused on the marketing, sales, and distribution of various products and services. A key area of its operations involves the energy sector, where DCC is significantly involved in the distribution of oil and liquefied petroleum gas across various markets. Additionally, it has a growing presence in the healthcare industry, providing products and services including pharmaceuticals and medical devices. DCC has also made strategic acquisitions to strengthen its technology segment, enhancing its supply chain and retail solutions. These activities underscore DCC's commitment to expanding its influence and operational scope across essential industries, supporting its strategic goal of sustained growth and market penetration.
AI+ Ask Fintel’s AI assistant about DCC plc - Depositary Receipt (Common Stock).
Thinking about good questions…
Basic Stats
The share price of DCC plc - Depositary Receipt (Common Stock) as of December 30, 2022 is $22.55 / share.
The Factor Analysis chart (below right) shows a view of DCC plc - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 98.91 MM |
| Earnings Date | |
| EPS (TTM) | 2.09 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-05-27 |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.10 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.02 |
| ROE | 0.07 |
| ROIC | 0.04 |
| CROIC | 0.01 |
| OCROIC | 0.11 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for DCC plc - Depositary Receipt (Common Stock) is $43.72. The forecasts range from a low of $30.96 to a high of $64.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for DCC plc - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2017-05-09 | Jefferies | Buy | Reiterate | |
| 2024-06-06 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2024-05-15 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2024-05-07 | Deutsche | Buy | Reiterate | |
| 2023-09-08 | Peel Hunt Limited | Buy | Reiterate | |
| 2023-09-05 | Berenberg Bank | Buy | Reiterate | |
| 2023-05-16 | Peel Hunt Limited | Buy | Reiterate | |
| 2023-01-19 | Numis | Buy | Initiate | |
| 2022-11-14 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2022-11-11 | Barclays | Underweight | Reiterate | |
| 2022-09-09 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-07-19 | Barclays | Underweight | Reiterate | |
| 2022-07-18 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-05-18 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-05-17 | Berenberg Bank | Buy | Reiterate | |
| 2017-05-30 | Canaccord Genuity | Buy | Reiterate | |
| 2017-05-16 | Canaccord Genuity | Buy | Reiterate | |
| 2022-05-11 | Morgan Stanley | Overweight | Reiterate | |
| 2022-05-05 | Berenberg Bank | Buy | Reiterate | |
| 2022-04-14 | Morgan Stanley | Overweight | Reiterate | |
| 2022-02-09 | Morgan Stanley | Reiteration | Reiterate | |
| 2021-12-16 | JP Morgan Cazenove | Reiteration | Reiterate | |
| 2021-12-01 | Berenberg Bank | Reiteration | Reiterate | |
| 2021-11-24 | Barclays | Reiteration | Reiterate | |
| 2021-11-10 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2021-10-01 | Berenberg Bank | Buy | Reiterate | |
| 2021-06-10 | Barclays | Equal-weight | Reiterate | |
| 2021-05-25 | Berenberg Bank | Buy | Reiterate | |
| 2021-05-21 | RBC Capital Markets | Outperform | Reiterate | |
| 2021-05-19 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2021-05-18 | Peel Hunt LLP | Buy | Reiterate | |
| 2021-05-13 | Berenberg Bank | Buy | Reiterate | |
| 2021-01-14 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2020-11-19 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2020-11-19 | Berenberg Bank | Buy | Reiterate | |
| 2020-05-20 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2020-01-24 | Berenberg Bank | Buy | Reiterate | |
| 2020-01-13 | HSBC | Buy | Reiterate | |
| 2019-11-12 | Peel Hunt LLP | Add | Reiterate | |
| 2019-07-12 | Berenberg Bank | Buy | Reiterate | |
| 2019-02-05 | Peel Hunt LLP | Add | Reiterate | |
| 2019-02-05 | Canaccord Genuity | Buy | Reiterate | |
| 2019-02-05 | UBS | Buy | Reiterate | |
| 2018-09-27 | Canaccord Genuity | Buy | Reiterate | |
| 2018-09-07 | RBC Capital Markets | Outperform | Reiterate | |
| 2018-07-31 | Berenberg Bank | Buy | Reiterate | |
| 2018-07-13 | Canaccord Genuity | Buy | Reiterate | |
| 2018-07-13 | Berenberg Bank | Buy | Reiterate | |
| 2018-07-13 | UBS | Buy | Reiterate | |
| 2018-07-05 | Berenberg Bank | Buy | Reiterate | |
| 2018-05-17 | Berenberg Bank | Buy | Reiterate | |
| 2018-05-15 | Canaccord Genuity | Buy | Reiterate | |
| 2017-11-17 | Berenberg Bank | Buy | Reiterate | |
| 2017-11-15 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-11-07 | Canaccord Genuity | Buy | Reiterate | |
| 2017-11-07 | Berenberg Bank | Buy | Reiterate | |
| 2017-11-07 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-06-01 | Goldman Sachs | Buy | Reiterate | |
| 2017-04-21 | Berenberg Bank | Buy | Reiterate | |
| 2017-03-27 | Goldman Sachs | Buy | Reiterate | |
| 2017-02-09 | Canaccord Genuity | Buy | Reiterate | |
| 2017-02-08 | UBS | Buy | Reiterate | |
| 2017-02-08 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2017-01-30 | Goldman Sachs | Buy | Reiterate | |
| 2016-11-24 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-11-16 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-11-14 | Canaccord Genuity | Buy | Reiterate | |
| 2016-11-14 | UBS | Buy | Reiterate | |
| 2016-10-27 | Canaccord Genuity | Buy | Initiate | |
| 2016-10-24 | Berenberg Bank | Buy | Reiterate | |
| 2016-09-12 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-09-08 | Goldman Sachs | Neutral | Reiterate | |
| 2016-08-22 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-08-01 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-07-28 | Berenberg Bank | Buy | Reiterate | |
| 2016-07-18 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-06-27 | Goldman Sachs | Neutral | Reiterate | |
| 2016-06-02 | Goldman Sachs | Neutral | Reiterate | |
| 2016-05-18 | Exane BNP Paribas | Neutral | Reiterate | |
| 2016-05-18 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-03-29 | Jefferies | Buy | Reiterate | |
| 2016-03-24 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2016-03-07 | Exane BNP Paribas | Outperform | Reiterate | |
| 2016-02-24 | Investec | Hold | Reiterate | |
| 2016-02-11 | Panmure Gordon | Buy | Reiterate | |
| 2016-02-05 | UBS | Buy | Reiterate | |
| 2016-02-01 | Exane BNP Paribas | Outperform | Reiterate | |
| 2016-01-21 | UBS | Buy | Reiterate | |
| 2015-12-03 | Peel Hunt LLP | Add | Reiterate | |
| 2015-11-19 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-11-11 | Berenberg Bank | Buy | Reiterate | |
| 2015-11-11 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-10-01 | Jefferies | Buy | Reiterate | |
| 2015-09-17 | Exane BNP Paribas | Outperform | Reiterate | |
| 2015-07-20 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-07-17 | Panmure Gordon | Buy | Reiterate | |
| 2015-06-05 | UBS | Buy | Reiterate | |
| 2015-06-05 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-06-01 | Jefferies | Buy | Reiterate | |
| 2015-05-26 | Berenberg Bank | Buy | Reiterate | |
| 2015-05-20 | Investec | Hold | Reiterate | |
| 2015-05-20 | Panmure Gordon | Buy | Reiterate | |
| 2015-05-19 | Panmure Gordon | Buy | Reiterate | |
| 2015-05-11 | Berenberg Bank | Buy | Reiterate | |
| 2015-04-20 | Panmure Gordon | Buy | Reiterate | |
| 2015-03-06 | Berenberg Bank | Buy | Reiterate | |
| 2015-02-12 | Panmure Gordon | Buy | Reiterate | |
| 2014-11-17 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-11-04 | Investec | Buy | Reiterate | |
| 2014-11-04 | Panmure Gordon | Buy | Reiterate | |
| 2014-11-04 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-10-01 | Goodbody | Buy | Reiterate | |
| 2014-10-01 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-08-28 | Peel Hunt LLP | Buy | Reiterate | |
| 2014-08-28 | Panmure Gordon | Buy | Reiterate | |
| 2014-07-18 | Panmure Gordon | Buy | Reiterate | |
| 2014-07-14 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-06-06 | Investec | Hold | Reiterate | |
| 2014-06-04 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-05-23 | UBS | Buy | Reiterate | |
| 2014-05-21 | Investec | Hold | Reiterate | |
| 2014-02-27 | Panmure Gordon | Buy | Reiterate | |
| 2014-02-21 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-02-18 | Jefferies | Buy | Reiterate | |
| 2014-02-17 | Seymour Pierce | Buy | Reiterate | |
| 2014-02-17 | Investec | Add | Reiterate | |
| 2014-01-22 | Jefferies | Buy | Reiterate | |
| 2014-01-20 | Seymour Pierce | Buy | Reiterate | |
| 2013-12-05 | UBS | Buy | Initiate | |
| 2013-11-06 | Jefferies | Buy | Reiterate | |
| 2013-10-31 | Davy | Outperform | Reiterate | |
| 2013-10-23 | Jefferies | Buy | Reiterate | |
| 2013-10-22 | Seymour Pierce | Buy | Initiate | |
| 2013-09-09 | Investec | Hold | Reiterate | |
| 2013-09-09 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2013-09-06 | Jefferies | Buy | Reiterate | |
| 2024-11-12 | Berenberg Bank | Buy | Reiterate | |
| 2025-07-11 | Deutsche | Hold | Reiterate | |
| 2025-09-02 | Berenberg Bank | Buy | Reiterate | |
| 2025-05-19 | RBC Capital Markets | Outperform | Reiterate |
